MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 9, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 24.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 9, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| January 4, 2027 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Trial Milestone | Phase 3 |
| February 4, 2028 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | Trial Milestone | Phase 3 |
| June 13, 2028 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa | Trial Milestone | Phase 3 |
Track MLTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MLTX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.